(2018) Evaluating the expression of cyclooxygenase-2 enzyme by immunohistochemistry in normal and tumoral tissue before and after neoadjuvant chemoradiotherapy in patients with esophageal cancer in Khorasan Province. Journal of cancer research and therapeutics. pp. 509-515. ISSN 1998-4138 (Electronic) 1998-4138 (Linking)
|
Text
JCanResTher143509-199688_053248.pdf Download (1MB) | Preview |
Abstract
Background: Esophageal cancer is the third most common cancer in Iran. Neoadjuvant chemoradiotherapy (NCRT) is the appropriate treatment for esophageal cancer. Aim: This study investigated the expression of cyclooxygenase (COX)-2 enzyme in normal and tumoral tissues before any treatment in patients with esophageal cancer, this study also assessed the effect of NCRT on the expression of COX-2 enzyme in normal and tumoral tissue in samples derived by surgery furthermore, and this study investigated the relationship between expression of COX-2 enzyme and the pathologic tumor regression grade (PTRG) patients. Materials and Methods: In this study, a total of 120 patients admitted to Omid Hospital, Imam Reza Hospitals, and Reza-Mashhad Medical Center, who were treated with NCRT, were recruited and the expression of the COX-2 enzyme in normal and tumoral tissues was assessed by immunohistochemistry before and after treatment by an expert pathologist between zero and 300. PTRG was determined by a pathologist after treatment. Results: The mean levels of COX-2 expression, obtained from tumoral and normal tissue baseline biopsy in patients, were 177.69 and 64.29, respectively, while in surgical specimen were 177.25 and 49.84, respectively. A significant association was found between PTRG of surgical specimen and COX-2 expression in normal tissue (baseline biopsy) at diagnosis (P = 0.034). Conclusions: The results indicated that expression of COX-2 in tumoral tissues exceeds the expression of COX-2 in normal tissue of the baseline biopsy. Patients with a high expression of COX-2 in baseline tumor biopsies had less response to treatment of pathology compared to patients with lower expression of COX-2 in baseline tumor biopsies.
Item Type: | Article |
---|---|
Keywords: | Celecoxib; esophageal cancer; neoadjuvant chemoradiotherapy; pathologic tumor regression grade |
Page Range: | pp. 509-515 |
Journal or Publication Title: | Journal of cancer research and therapeutics |
Journal Index: | ISI, Pubmed, Scopus |
Volume: | 14 |
Number: | 3 |
Identification Number: | 10.4103/0973-1482.199428 |
ISSN: | 1998-4138 (Electronic) 1998-4138 (Linking) |
Depositing User: | دکتر محبوبه عبداللهی |
URI: | http://eprints.thums.ac.ir/id/eprint/647 |
Actions (login required)
View Item |